Significant advances in the diagnosis and treatment of large B-cell lymphoma have driven the development of new guidelines, published in the British Journal of Haematology.
In a key change from the last iteration in 2016, the 2024 guideline has been split into two separate guidance documents as clinical management, diagnostic aspects, and treatment options have become increasingly complicated, lead author Professor Chris Fox, Consultant Clinical Haematologist at Nottingham University Hospitals NHS Trust, UK, told the limbic.
The first of these to be published concerns newly diagnosed and first-line treatment of LBCL [link here], while the second, to be published later this year, will advise on relapsed or refractory disease and subsequent lines of therapy.
With regard to diagnosis, clinical haematologists should be aware that invasive procedures such as bone marrow biopsies are now no longer necessary in most patients because of improved imaging, such as PET CT, “which is now widely available and very important for accurate staging”, Professor Fox noted.
According to the guideline, “PET-CT is more likely than bone marrow biopsy to detect marrow involvement with LBCL, and the presence of non-avid bone marrow disease does not confer a worse prognosis”.
“Bone marrow biopsy may be considered for selected patients in whom a co-existing haematological condition is suspected (e.g. low-grade lymphoma or myelodysplasia), and where this would inform clinical management, but is otherwise unnecessary”.
The guideline also outlines additional genetic tests that can be performed in patients as part of initial risk assessment, such as FISH for MYC and BCL rearrangements.
“MYC translocation to an immunoglobulin partner is most strongly associated with inferior overall survival,” the authors noted, but other predictors of poor outcome such as TP53 mutations and ‘molecular high-grade’ gene expression signature “are not yet routinely used in clinical prognostication,” they said.
Management
On the treatment side, the guideline includes more detailed advice on how best to manage stage one and stage two disease, and the patients potentially eligible for more limited treatment and less chemotherapy, as guided by PET scanning.
Of note, polatuzumab vedotin in combination with chemotherapy has been newly added as a treatment option for patients with certain risk factors.